RECRUIT-TandAbs®: Harnessing the immune system to kill cancer cells

Future Oncology

Volumn 8, Issue 6, 2012, Pages 687-695

  McAleese, Fionnuala ^a   Eser, Markus ^a  

^a Affimed GmbH   (Germany)

Author keywords

antibody; bispecific; CD19; CD30; diabody; Hodgkins lymphoma; non Hodgkins lymphoma; TandAb

Indexed keywords

BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; TANDAB; TANDEM DIABODIES; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE SYSTEM; LYMPHOMA; MOLECULAR WEIGHT; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMISTRY; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD30; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KILLER CELLS, NATURAL; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84863650195     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.54     Document Type: Review

References (52)

1. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 314(6012), 628-631 (1985).
2. Karpovsky B, Titus JA, Stephany DA, Segal DM. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med. 160(6), 1686-1701 (1984).
3. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316(6026), 354-356 (1985).
4. Cochran JR. Engineered proteins pull double duty. Sci. Transl Med. 2(17), 17ps5 (2010).
5. Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab. Final results from an international multicenter, Phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113(10), 2714-2723 (2008).
6. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69(12), 4941-4944 (2009).
7. Johnson S, Burke S, Huang L et al. Effector cell recruitment with novel Fv-based dual-Affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399(3), 436-449 (2010).
8. Kipriyanov SM, Moldenhauer G, Schuhmacher J et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293(1), 41-56 (1999).
9. Bostrom J, Yu SF, Kan D et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323(5921), 1610-1614 (2009).
10. Doppalapudi VR, Huang J, Liu D et al. Chemical generation of bispecific antibodies. Proc. Natl Acad. Sci. USA 107(52), 22611-22616 (2010).
11. Wu C, Ying H, Bose S et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1(4), 339-347 (2009).
12. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther. 2(1), 19-31 (2007).
13. Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr. Opin Biotechnol. 22(6), 849-857 (2011).
14. Lipovsek D. Adnectins: E ngineered target-binding protein therapeutics. Protein Eng. Des. Sel. 24(1-2), 3-9 (2011).
15. Skerra A. Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 275(11), 2677-2683 (2008).
16. Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov. Today 13(15-16), 695-701 (2008).
17. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin Mol. Ther.
18. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24(2), 89-98 (2010).
19. Chames P, Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? MAbs 1(6), 539-547 (2009).
20. Seimetz D. Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (Removab). J. Cancer 2, 309-316 (2011).
21. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155(1), 219-225 (1995).
22. Chelius D, Ruf P, Gruber P et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2(3), 309-319 (2010).
23. Zeidler R, Mysliwietz J, Csanady M et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer 83(2), 261-266 (2000).
24. Zeidler R, Reisbach G, Wollenberg B et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163(3), 1246-1252 (1999).
25. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl Acad. Sci. USA 92(15), 7021-7025 (1995).
26. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
27. Topp MS, Kufer P, Gokbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29(18), 2493-2498 (2011).
28. Brischwein K, Schlereth B, Guller B et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43(8), 1129-1143 (2006).
29. Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol. Biol. 562, 177-193 (2009).
30. Holliger P, Prospero T, Winter G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90(14), 6444-6448 (1993).
31. Kipriyanov SM, Moldenhauer G, Braunagel M et al. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 330(1), 99-111 (2003).
32. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel. 17(4), 357-366 (2004).
33. Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp. Cell Res. 317(9), 1278-1285 (2011).
34. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, De Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90(3), 1109-1114 (1997).
35. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789-1796 (2008).
36. Treon SP, Hansen M, Branagan AR et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol. 23(3), 474-481 (2005).
37. Eichenauer DA, Fuchs M, Borchmann P, Engert A; German Hodgkin Study Group. Hodgkin's lymphoma: Current treatment strategies and novel approaches. Expert Rev. Hematol. 1(1), 63-73 (2008).
38. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem. Pharmacol. 79(11), 1544-1552 (2010).
39. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv. Exp. Med. Biol. 647, 174-185 (2009).
40. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010).
41. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
42. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res. 13(2 Pt 1), 388-397 (2007).
43. Wahlin BE, Sundstrom C, Holte H et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin. Cancer Res. 17(12), 4136-4144 (2011).
44. Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines. Vaccine 27(25-26), 3398-3400 (2009).
45. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol. Ther. 7(8), 1245-1256 (2007).
46. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
47. Dave VP. Hierarchical role of CD3 chains in thymocyte development. Immunol. Rev. 232(1), 22-33 (2009).
48. Chatenoud L, Bluestone JA. CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7(8), 622-632 (2007).
49. Renders L, Valerius T. Engineered CD3 antibodies for immunosuppression. Clin. Exp. Immunol. 133(3), 307-309 (2003).
50. Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth. J. Med. 67(8), 311-321 (2009).
51. Moore PA, Zhang W, Rainey GJ et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117(17), 4542-4551 (2011).
52. Cochlovius B, Kipriyanov SM, Stassar MJ et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 CD19 tandem diabody, and CD28 costimulation. Cancer Res. 60(16), 4336-4341 (2000).